HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shiseido forecast

This article was originally published in The Rose Sheet

Executive Summary

Consolidated net income for fiscal 2004 (ended March 31) will be $235.1 mil. (¥1=$.01), about 8.7% higher than originally forecast after company receives approval from Japanese Minister of Health, Labor and Welfare for return of a portion of employees' pension fund, company announces. Extraordinary income derived from the return will be "partially offset by expenses entailed in structural reform of businesses," Japanese cosmetics firm says. Net sales are expected to be about 1.1% lower to $5.96 bil. Exemption from future payment obligations for a portion of employee's pension fund was granted by the agency on Feb. 25, Shiseido notes...

You may also be interested in...



Shiseido Domestic Rejuvenation, Globalization Efforts Underway

Japanese cosmetics manufacturer Shiseido is focused on rejuvenating its domestic business and expanding globally as part of an initiative to transform the company into a "more profit-oriented" operation, the firm said in a fiscal 2004 (ended March 31) sales and earnings release

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel